Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis)

Abstract Introduction Tildrakizumab is a monoclonal antibody targeting interleukin (IL)-23 approved for the treatment of moderate-to-severe plaque psoriasis across two different dosages (100 mg and 200 mg). The higher dosage is recommended for patients with a body weight ≥ 90 kg or a high disease bu...

Descrición completa

Detalles Bibliográficos

Principais autores:	Mario Valenti, Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Francesco Loconsole, Martina Burlando, Anna E. Cagni, Norma Cameli, Carlo G. Carrera, Andrea Carugno, Aldo Cuccia, Paolo Dapavo, Eugenia V. Di Brizzi, Valentina Dini, Maria C. Fargnoli, Francesca M. Gaiani, Claudio Guarneri, Claudia Lasagni, Gaetano Licata, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Alessandra Michelucci, Maria L. Musumeci, Diego Orsini, Romina Ortega, Luca Potestio, Luca Rapparini, Simone Ribero, Francesca Satolli, Davide Strippoli, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Pina Brianti, Antonio Costanzo, Alessandra Narcisi
Formato:	Artigo
Idioma:	Inglês
Publicado:	Adis, Springer Healthcare 2025-04-01
Series:	Dermatology and Therapy
Assuntos:	Anti-IL-23 Biologics Psoriasis Real-Life Tildrakizumab
Acceso en liña:	https://doi.org/10.1007/s13555-025-01416-z
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!